Granules India’s Unit V facility located at Anakapally, Visakhapatnam, Andhra Pradesh, India has successfully completed the US Food and Drug Administration (FDA) inspection between April 8-12 2024, resulting in zero 483 observations.
Pharmaceutical major Granules India announced on Friday, April 12, that its Unit V facility located at Anakapally, Visakhapatnam in Andhra…
Paracetamol maker Granules India posts marginal rise in Q3 profit
Granules` Generic Sildenafil Citrate Receives Approval in the U.S.
Granules India gets USFDA nod for generic drug used for short-term treatment of heartburn
HYDERABAD, Aug 9 (Reuters) - Granules India Ltd (GRAN.NS), the maker of paracetamol and ibuprofen pain relievers, reported a 62.5% fall in first-quarter profit on Wednesday, as a cyber security incident significantly disrupted operations.
Granules' Generic Metoprolol Succinate Receives Approval in US
Granules India, a leading vertically integrated pharmaceutical company, joined forces with the Central Bureau of Narcotics to spread impactful awareness against drug abuse on the occasion of the International Day against Drug Abuse and Illicit Trafficking. Contributing to the Bureau’s vision to create a drug-free society, Granules organized a series of engaging activities aimed at educating the public about the dangers of illicit drugs.
BENGALURU, June 29 (Reuters) - Granules India (GRAN.NS) on Thursday warned of a significant loss of revenue and profitability due to a cyber security attack that the pharmaceuticals company faced late last month.
Granules' Generic Levetiracetam Receives Approval in the U.S.